Survival of HIV-infected patients with compensated liver cirrhosis

AIDS

Volumn 24, Issue 5, 2010, Pages 745-753

  Tuma, Paula ^a   Jarrin, Inmaculada ^b   Del Amo, Julia ^b   Vispo, Eugenia ^a   Medrano, Jose ^a   Martin Carbonero, Luz ^a   Labarga, Pablo ^a   Barreiro, Pablo ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b CARLOS III INSTITUTE OF HEALTH   (Spain)

Author keywords

Child Pugh score; Elastometry; Hepatitis C; HIV; Liver cirrhosis; Model for End Stage Liver Disease score; Mortality

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL EXAMINATION; CLINICAL TRIAL; DELTA AGENT HEPATITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ELASTOGRAPHY; FEMALE; HEPATIC ELASTOMETRY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION TEST; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; VIRUS DETECTION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 77949422411     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283366602     Document Type: Article

References (52)

1. Lefton H, Rosa A, Cohen M. Diagnosis and epidemiology of cirrhosis. Med Clin North Am 2009; 93:787-799.
2. Weber R, Sabin C, Friis-Moller N, Reiss P, El-Sadr W, Kirk O, et al. Liver-related deaths in persons infected with the HIV: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
3. Rosenthal E, Salmon-Ceron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19). HIV Med 2009; 10:282-289.
4. Núñez-Fernández C, Mart́in-Carbonero L, Valencia ME, Aguilera J, Garćia-Samaniego J, Gonzalez-Lahoz J, et al. Liver complications have reached a plateau as cause of hospital admission and death in HIV patients in Madrid. AIDS Res Hum Retroviruses 2009; 25:383-385.
5. Palella F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G, et al. Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med 1998; 338:853-860.
6. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
7. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. Hepatology 1999; 30:1054-1058.
8. Sulkowski M, Mehta S, Torbenson M, Higgins Y, Brinkley S, de Oca R, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21:2209-2216.
9. Macias J, Berenguer J, Japon M, Giron J, Rivero A, Lopez-Cortes L, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with HIV/hepatitis C virus. Hepatol-ogy 2009; 50:1056-1063.
10. Deng L, Gui X, Zhang Y, Gao S, Yang R. ImpactofHIV infection on the course of hepatitis C virus infection: a meta-analysis. World J Gastroenterol 2009; 15:996-1003.
11. Thio C, Seaberg E, Skolasky R, Phair J, Visscher B, Muñoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002; 360:1921-1926.
12. Martin-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, et al. Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38:128-133.
13. Thein H, Yi Q, Dore G, Krahn M. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22:1979-1991.
14. Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M, Torre-Cisneros J, Garcia-Garcia J, Arizcorreta A, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20:49-57.
15. Bruno R, Sacchi P, Puoti M, Maiocchi L, Patruno S, Carosi G, et al. Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. J Acquir Immune Defic Syndr 2007; 46:297-303.
16. Tan-Tam CC, Frassetto LA, Stock PG. Liver and kidney transplantation in HIV-infected patients. AIDS Rev 2009; 11:190-204.
17. Kazemi F, Kettaneh A, N'Kontchou G, Pinto E, Ganne-Carrie N, Trinchet J, et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol 2006; 45:230-235.
18. Soriano V, Mart́in-Carbonero L, Garćia-Samaniego J. Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis? AIDS 2003; 17:751-753.
19. Ganne-Carrie N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006; 44:1511-1517.
20. Kirk G, Astemborski J, Mehta S, Spoler C, Fisher C, Allen D, et al. Assessmentof liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coin-fection. Clin Infect Dis 2009; 48:963-972.
21. Kamath P, Wiesner R, Malinchoc M, Kremers W, Therneau T, Kosberg C, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464-470.
22. Botta F, Giannini E, Romagnoli P, Fasoli A, Malfatti F, Chiar-bonello B, et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut 2003; 52:134-139.
23. Boursier J, Cesbron E, Tropet A, Pilette C. Comparison and improvement of MELD and Child-Pugh score accuracies for the prediction of 6-month mortality in cirrhotic patients. J Clin Gastroenterol 2009; 43:580-585.
24. Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez J, Montero J, Torre-Cisneros J, et al. HIV coinfection shortens the survival of patients with HCV-related decompensated cirrhosis. Hepatology 2005; 41:779-789.
25. Maida I, Nuñez M, Gonzalez-Lahoz J, Soriano V. Liver transplantation in HIV-HCV coinfected candidates: what is the most appropriate time for evaluation? AIDS Res Human Retro-viruses 2005; 21:599-601.
26. Giron-Gonzalez J, Brun F, Terron A, Vergara A, Arizcorreta A. Natural history of compensated and decompensated HCV-related cirrhosis in HIV-infected patients: a prospective multi-center study. Antivir Ther 2007; 12:899-907.
27. Pineda JA, Aguilar-Guisado M, Rivero A, Giron-Gonzalez J, Ruiz-Morales J, Merino D, et al. Natural history of compensated HCV-related cirrhosis in HIV-infected patients. Clin Infect Dis 2009; 49:1274-1282.
28. Kluwe J,Predere J,Gwak G, MencinA,deMinicis S,Osterrrecher C, et al. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 2009. [Epub ahead of print]
29. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.
30. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elasto-graphy (FibroScan): a prospective study. Gut 2006; 55:403-408.
31. Malinchoc M, Kamath P, Gordon F, Peine C, Rank J, ter Borg P. A model to predict poor survival in patients undergoing trans-jugular intrahepatic portosystemic shunts. Hepatology 2000; 31:864-871.
32. Child C, Turcotte J. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1:1-85.
33. Navarro C. The National Death Index: a largely expected advance in the access to mortality data. Gac Sanit 2006; 20:421-423.
34. Kitahata M, Gange S, Abraham A, Merriman B, Saag M, Justice A, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
35. Pascual-Pareja J, Camino A, Larrauri C, Gonzalez-Garcia J, Montes M, Diez J, et al. HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 count of more than 350 cells/ microl at the time of liver biopsy. AIDS 2009; 23:971-975.
36. Brau N, Salvatore M, Rios-Bedoya C, Fernandez-Carbia A, Paronetto F, Rodriguez-Orengo J, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44:47-55.
37. Verma S, Wang C, Govindarajan S, Kanel G, Squires K, Bonacini M. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis 2006; 42:262-270.
38. Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M, Rios-Villegas MJ, Ruiz-Morales J, Rivero A, et al. Clinical progression of hepatitis C virus-related chronic liver disease in HIV-infected patients undergoing highly active antiretroviral therapy. Hepa-tology 2007; 46:622-630.
39. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713.
40. Bonacini M, Loie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004; 18:2039-2045.
41. Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother (in press).
42. Soriano V, Perno CF, Kaiser R, Calvez V, Gatell J, di Perri G, et al. When and how to use maraviroc in HIV-infected patients. AIDS 2009; 23:2377-2385.
43. HammerS, Eron J,Reiss P, Schooley R, Thompson M, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
44. DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents www.aidsinfo.nih.gov; February 2009.
45. Rockstroh J, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, et al. EACS guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-88.
46. Degos F, Christidis C, Ganne-Carrie N, Farmachidi J, Degott C, Guettier C, et al. Hepatitis C virus-related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47:131-136.
47. Sangiovanni A, Prati G, Fasani P, Ronchi P, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to HCV: a 17-year cohort study of 214 patients. Hepatology 2006; 43:1303-1310.
48. Barreiro P, Martin-Carbonero L, Nunez M, Rivas P, Morente A, Simarro N, et al. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3. Clin Infect Dis 2006; 42:1032-1039.
49. Castera L, Le B, Roudot-Thoraval F, Bernard P, Foucher J, Merrouche W, et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and noninvasive scores. J Hepatol 2009; 50:59-68.
50. Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastro-enterol 2009; 104:1147-1158.
51. Ragni M, Eghtesad B, Schlesinger K, Dvorchik I, Fung J. Pre-transplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005; 11:1425-1430.
52. Murillas J, Rimola A, Laguno M, de Lazzari E, Rascon J, Aguero F, et al. The model for end-stage liver disease score is the best prognostic factor in HIV-1-infected patients with end-stage liver disease: a prospective cohort study. Liver Transpl 2009; 15:1133-1141.